中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
4期
456-458
,共3页
王喜福%祖晓麟%王成钢%王旭%王硕%刘飞%朱小玲
王喜福%祖曉麟%王成鋼%王旭%王碩%劉飛%硃小玲
왕희복%조효린%왕성강%왕욱%왕석%류비%주소령
高脂血症%红细胞变形性%复方丹参滴丸
高脂血癥%紅細胞變形性%複方丹參滴汍
고지혈증%홍세포변형성%복방단삼적환
Hyperlipidemia%Erythrocyte deformability%Compound danshen dripping pills
目的 观察复方丹参滴丸对高脂血症患者红细胞变形性的影响,并探讨其可能的作用机制.方法 选取高脂血症患者100例,完全随机分为单药组和联合组,各50例.单药组予以瑞舒伐他汀钙10 mg/次,每晚1次口服；联合组在单药组基础上给予复方丹参滴丸10粒/次,3次/d口服.8周后检测红细胞变形性、红细胞膜Na+-K+-ATP酶活性及丙二醛含量的变化.结果 ①单药组治疗前TG、TC、LDL-C、HDL-C分别为(2.62±0.53)、(6.5±1.0)、(4.2±0.5)、(1.2±0.3)mmol/L,治疗后分别为(1.45±0.29)、(4.2±1.0)、(2.9±0.4)、(1.7±0.3)mmol/L,治疗前后差异均有统计学意义(P＜0.01或P＜0.05)；联合组治疗前TG、TC、LDL-C、HDL-C分别为(2.51±0.33)、(6.8±1.0)、(4.0±0.5)、(1.1±0.3)mmol/L,治疗后分别为(1.40±0.31)、(4.2±0.9)、(2.8 ±0.5)、(1.7±0.4)mmol/L,治疗前后差异均有统计学意义(P＜0.01或P＜0.05),治疗后组间差异无统计学意义(P＞0.05).②单药组和联合组治疗前红细胞变形指数分别为(56±4)％和(59±6)％,治疗后红细胞变形指数分别为(62±8)％和(69±8)％,组内治疗前后的差异及治疗后组间差异均有统计学意义(均P ＜0.05).③单药组和联合组治疗前红细胞膜Na+-K+-ATP酶活性分别为(0.57±0.06)和(0.61±0.07) μmol/(mg·min),治疗后分别为(0.81±0.09)和(1.05±0.11) μmol/(mg·min),组内治疗前后的差异及治疗后组间差异均有统计学意义(均P＜0.05).④单药组和联合组治疗前血浆丙二醛水平分别为(6.3±0.5)和(6.2±0.7) μmol/L (P ＜0.05),治疗后分别为(5.6±0.6)和(5.1±0.4)μmol/L,组内治疗前后的差异及治疗后组间差异均有统计学意义(均P＜0.05).结论 复方丹参滴丸能有效改善高脂血症患者红细胞变形性,提高红细胞通过微小血管的能力,其机制可能与降低脂质过氧化损伤以及提高红细胞膜Na+-K+-ATP酶活性有关.
目的 觀察複方丹參滴汍對高脂血癥患者紅細胞變形性的影響,併探討其可能的作用機製.方法 選取高脂血癥患者100例,完全隨機分為單藥組和聯閤組,各50例.單藥組予以瑞舒伐他汀鈣10 mg/次,每晚1次口服；聯閤組在單藥組基礎上給予複方丹參滴汍10粒/次,3次/d口服.8週後檢測紅細胞變形性、紅細胞膜Na+-K+-ATP酶活性及丙二醛含量的變化.結果 ①單藥組治療前TG、TC、LDL-C、HDL-C分彆為(2.62±0.53)、(6.5±1.0)、(4.2±0.5)、(1.2±0.3)mmol/L,治療後分彆為(1.45±0.29)、(4.2±1.0)、(2.9±0.4)、(1.7±0.3)mmol/L,治療前後差異均有統計學意義(P＜0.01或P＜0.05)；聯閤組治療前TG、TC、LDL-C、HDL-C分彆為(2.51±0.33)、(6.8±1.0)、(4.0±0.5)、(1.1±0.3)mmol/L,治療後分彆為(1.40±0.31)、(4.2±0.9)、(2.8 ±0.5)、(1.7±0.4)mmol/L,治療前後差異均有統計學意義(P＜0.01或P＜0.05),治療後組間差異無統計學意義(P＞0.05).②單藥組和聯閤組治療前紅細胞變形指數分彆為(56±4)％和(59±6)％,治療後紅細胞變形指數分彆為(62±8)％和(69±8)％,組內治療前後的差異及治療後組間差異均有統計學意義(均P ＜0.05).③單藥組和聯閤組治療前紅細胞膜Na+-K+-ATP酶活性分彆為(0.57±0.06)和(0.61±0.07) μmol/(mg·min),治療後分彆為(0.81±0.09)和(1.05±0.11) μmol/(mg·min),組內治療前後的差異及治療後組間差異均有統計學意義(均P＜0.05).④單藥組和聯閤組治療前血漿丙二醛水平分彆為(6.3±0.5)和(6.2±0.7) μmol/L (P ＜0.05),治療後分彆為(5.6±0.6)和(5.1±0.4)μmol/L,組內治療前後的差異及治療後組間差異均有統計學意義(均P＜0.05).結論 複方丹參滴汍能有效改善高脂血癥患者紅細胞變形性,提高紅細胞通過微小血管的能力,其機製可能與降低脂質過氧化損傷以及提高紅細胞膜Na+-K+-ATP酶活性有關.
목적 관찰복방단삼적환대고지혈증환자홍세포변형성적영향,병탐토기가능적작용궤제.방법 선취고지혈증환자100례,완전수궤분위단약조화연합조,각50례.단약조여이서서벌타정개10 mg/차,매만1차구복；연합조재단약조기출상급여복방단삼적환10립/차,3차/d구복.8주후검측홍세포변형성、홍세포막Na+-K+-ATP매활성급병이철함량적변화.결과 ①단약조치료전TG、TC、LDL-C、HDL-C분별위(2.62±0.53)、(6.5±1.0)、(4.2±0.5)、(1.2±0.3)mmol/L,치료후분별위(1.45±0.29)、(4.2±1.0)、(2.9±0.4)、(1.7±0.3)mmol/L,치료전후차이균유통계학의의(P＜0.01혹P＜0.05)；연합조치료전TG、TC、LDL-C、HDL-C분별위(2.51±0.33)、(6.8±1.0)、(4.0±0.5)、(1.1±0.3)mmol/L,치료후분별위(1.40±0.31)、(4.2±0.9)、(2.8 ±0.5)、(1.7±0.4)mmol/L,치료전후차이균유통계학의의(P＜0.01혹P＜0.05),치료후조간차이무통계학의의(P＞0.05).②단약조화연합조치료전홍세포변형지수분별위(56±4)％화(59±6)％,치료후홍세포변형지수분별위(62±8)％화(69±8)％,조내치료전후적차이급치료후조간차이균유통계학의의(균P ＜0.05).③단약조화연합조치료전홍세포막Na+-K+-ATP매활성분별위(0.57±0.06)화(0.61±0.07) μmol/(mg·min),치료후분별위(0.81±0.09)화(1.05±0.11) μmol/(mg·min),조내치료전후적차이급치료후조간차이균유통계학의의(균P＜0.05).④단약조화연합조치료전혈장병이철수평분별위(6.3±0.5)화(6.2±0.7) μmol/L (P ＜0.05),치료후분별위(5.6±0.6)화(5.1±0.4)μmol/L,조내치료전후적차이급치료후조간차이균유통계학의의(균P＜0.05).결론 복방단삼적환능유효개선고지혈증환자홍세포변형성,제고홍세포통과미소혈관적능력,기궤제가능여강저지질과양화손상이급제고홍세포막Na+-K+-ATP매활성유관.
Objective To observe the effect of compound Danshen dripping pill on deformation index of red blood cell (RBC) in patients with hyperlipidemia,and to explore its possible mechanism.Methods We chosen 100 patients with hyperlipidemia from Jul.2009 to Aug.2011 from out-patient of cardiology in Anzhen hospital.All the patients were randomly divided into two groups:pure administration group(n =50)and combined administration group(n =50).The pure administration group was administered with rosuvastatin calcium (10 mg/night),and combined administration group was administered with compound Danshen dripping pill(30 pill/d) besides rosuvastatin calcium (10 mg/night).Eight weeks later,blood lipids level,deformation index of RBC,activity of Na+-K+-ATP enzymes of RBC membrane,and plasma malondialdehyde (MDA) level were measured.The same parameters were also tested from the blood samples of 30 healthy volunteers which served as control.Results ①Levels of triglyceride(TG),total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in pure administration group were (2.62 ± 0.53),(6.5 ± 1.0),(4.2 ± 0.5),(1.2 ± 0.3)mmol/L,respectively.After the treatment,these parameters were (1.45 ± 0.29),(4.2 ± 1.0),(2.9 ± 0.4),(1.7 ± 0.3) mmol/L,respectively.There were significant differences between the data before and after treatment (P ＜0.01 or P ＜0.05).Levels of TG,TC,LDL-C and HDL-C in combined administration group were (2.51 ±0.33),(6.8 ± 1.0),(4.0 ± 0.5),(1.1 ± 0.3) mmol/L,respectively.After the treatment,they were (1.40 ±0.31),(4.2 ± 0.9),(2.8 ± 0.5),(1.7 ± 0.4) mmol/L,respectively,which were significantly different with those before the treatment (P ＜ 0.01 or P ＜ 0.05).②The RBC deformation index of pure administration group was (56 ± 4) ％,and that of combined administration group was (59 ± 6) ％ before treatment; After treatment,the RBC deformation index of pure administration group was (62 ± 8) ％,and that of combined administration group was (69 ± 8) ％.There were significant differences in either internal or external group before and after treatment (P ＜0.05).③The activities of Na +-K +-ATP ase were (0.57 ± 0.06) and (0.61 ± 0.07) μmol/(mg · min) in pure and combined administration groups before the treatment.After the treatment,they became (0.81 ± 0.09) and (1.05 ± 0.11) μmol/(mg · min),which were significantly different from the data before the treatment (P ＜0.05).④After the treatment,the blood MDA levels decreased from (6.3 ± 0.5) to (5.6 ± 0.6) μmol/L (P ＜0.05) in pure administration group and decreased from (6.2 ± 0.7) to (5.1 ± 0.4) μmol/L (P ＜ 0.05) in combined administration group.There was also significant difference between the groups.Conclusions Compound Danshen dripping pill can significantly improve RBC deformation index of patients with hyperlipidemia.The possible mechanisms may be related to the elevation of Na +-K +-ATP enzymes of RBC membrane and the reduction of blood MDA level.
